Your browser doesn't support javascript.
loading
Outcomes of Various Classes of Oral Antidiabetic Drugs on Nonalcoholic Fatty Liver Disease.
Jang, Heejoon; Kim, Yeonjin; Lee, Dong Hyeon; Joo, Sae Kyung; Koo, Bo Kyung; Lim, Soo; Lee, Woojoo; Kim, Won.
Affiliation
  • Jang H; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul Metropolitan Government Boramae Medical Center, Seoul, Republic of Korea.
  • Kim Y; Department of Public Health Sciences, Graduate School of Public Health, Seoul National University, Seoul, Republic of Korea.
  • Lee DH; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul Metropolitan Government Boramae Medical Center, Seoul, Republic of Korea.
  • Joo SK; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul Metropolitan Government Boramae Medical Center, Seoul, Republic of Korea.
  • Koo BK; Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul National University College of Medicine, Seoul Metropolitan Government Boramae Medical Center, Seoul, Republic of Korea.
  • Lim S; Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
  • Lee W; Department of Public Health Sciences, Graduate School of Public Health, Seoul National University, Seoul, Republic of Korea.
  • Kim W; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul Metropolitan Government Boramae Medical Center, Seoul, Republic of Korea.
JAMA Intern Med ; 184(4): 375-383, 2024 Apr 01.
Article in En | MEDLINE | ID: mdl-38345802
ABSTRACT
Importance Several oral antidiabetic drug (OAD) classes can potentially improve patient outcomes in nonalcoholic fatty liver disease (NAFLD) to varying degrees, but clinical data on which class is favored are lacking.

Objective:

To investigate which OAD is associated with the best patient outcomes in NAFLD and type 2 diabetes (T2D). Design, Setting, and

Participants:

This retrospective nonrandomized interventional cohort study used the National Health Information Database, which provided population-level data for Korea. This study involved patients with T2D and concomitant NAFLD. Exposures Receiving either sodium-glucose cotransporter 2 (SGLT2) inhibitors, thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors, or sulfonylureas, each combined with metformin for 80% or more of 90 consecutive days. Main Outcomes and

Measures:

The main outcomes were NAFLD regression assessed by the fatty liver index and composite liver-related outcome (defined as liver-related hospitalization, liver-related mortality, liver transplant, and hepatocellular carcinoma) using the Fine-Gray model regarding competing risks.

Results:

In total, 80 178 patients (mean [SD] age, 58.5 [11.9] years; 43 007 [53.6%] male) were followed up for 219 941 person-years, with 4102 patients experiencing NAFLD regression. When compared with sulfonylureas, SGLT2 inhibitors (adjusted subdistribution hazard ratio [ASHR], 1.99 [95% CI, 1.75-2.27]), thiazolidinediones (ASHR, 1.70 [95% CI, 1.41-2.05]), and DPP-4 inhibitors (ASHR, 1.45 [95% CI, 1.31-1.59]) were associated with NAFLD regression. SGLT2 inhibitors were associated with a higher likelihood of NAFLD regression when compared with thiazolidinediones (ASHR, 1.40 [95% CI, 1.12-1.75]) and DPP-4 inhibitors (ASHR, 1.45 [95% CI, 1.30-1.62]). Only SGLT2 inhibitors (ASHR, 0.37 [95% CI, 0.17-0.82]), not thiazolidinediones or DPP-4 inhibitors, were significantly associated with lower incidence rates of adverse liver-related outcomes when compared with sulfonylureas. Conclusions and Relevance The results of this cohort study suggest that physicians may lean towards prescribing SGLT2 inhibitors as the preferred OAD for individuals with NAFLD and T2D, considering their potential benefits in NAFLD regression and lower incidences of adverse liver-related outcomes. This observational study should prompt future research to determine whether prescribing practices might merit reexamination.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thiazolidinediones / Diabetes Mellitus, Type 2 / Dipeptidyl-Peptidase IV Inhibitors / Non-alcoholic Fatty Liver Disease / Sodium-Glucose Transporter 2 Inhibitors Type of study: Observational_studies / Risk_factors_studies Limits: Female / Humans / Male / Middle aged Language: En Journal: JAMA Intern Med Year: 2024 Document type: Article Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thiazolidinediones / Diabetes Mellitus, Type 2 / Dipeptidyl-Peptidase IV Inhibitors / Non-alcoholic Fatty Liver Disease / Sodium-Glucose Transporter 2 Inhibitors Type of study: Observational_studies / Risk_factors_studies Limits: Female / Humans / Male / Middle aged Language: En Journal: JAMA Intern Med Year: 2024 Document type: Article Country of publication: